Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Sailajah GukathasanDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Chibuzor OleleweDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Libby RatliffDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.ORCID 0000-0002-0187-9921
Jong H KimDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Alyson M AckermanDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.ORCID 0000-0001-5609-0509
J Robert McCorkleCenter for Pharmaceutical Research and Innovation, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, United States.
Sean ParkinDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Gunnar F KwakyeDepartment of Neuroscience, Oberlin College, Oberlin, Ohio 44074, United States.
Jill M KolesarCenter for Pharmaceutical Research and Innovation, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, United States.
Samuel G AwuahDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.ORCID 0000-0003-4947-7283
Funding
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI Jon Scott Thorson · 2020 to 2026
$18.7M
Gold-derived Therapeutic Compounds for Disease ApplicationR01CA258421 · NCI · UNIVERSITY OF KENTUCKY · PI AWUAH, SAMUEL GORMAN · 2021 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Chemoproteomic Profiling of a Carbon-Stabilized Gold(III) Macrocycle Reveals Cellular Engagement with HMOX2. · full record | OpenQuestion